Just a moment, the page is loading...
The Supported Studies Programme

Vaccines



Timelines





Please find below the current areas of interest for Vaccines Human Subject Research - 2024 Cycle 1.

[RSV]
• Studies on risk factors of RSV disease, burden of disease and downstream impact/sequela in adults at increased risk of RSV diseases.
• Studies to assess GSK's RSV vaccine's immunogenicity and/or real-world effectiveness/impact in adult population at increased risk of RSV disease.
• Studies to assess vaccine-induced immunity mechanisms against RSV in adults.

[Neisseria]
• Effectiveness, impact, and duration of protection of 4CMenB/MenACWY-CRM vaccination programs in specific ages and settings, including IMD and carriage.
• Short- and long-term impact of IMD on quality of life of patients, caregivers and healthcare systems.

[Pertussis]
• Pertussis burden of diseases in adults and patients with chronic diseases.

[Rotavirus]
• Impact of Rotavirus vaccination on strain epidemiology.

[Streptococcus Pneumoniae]
• Studies to investigate the evolving serotype-specific pneumococcal disease burden (incl. epidemiological and/or economic endpoints) in adult and pediatric populations.

[Hepatitis]
• Long-term protection with hepatitis vaccines in infant and adult populations.

[Herpes Zoster]
• Studies to further understand the burden and impact of HZ and its complications, including impact on underlying conditions.
• Studies to further understand the benefits of HZ prevention in indicated populations, including but not limited to cardiovascular risks and impact on concurrent underlying chronic diseases.
• Studies to assess GSK's recombinant zoster vaccine immunogenicity and/or real-world effectiveness/impact in adult populations at risk of Zoster disease, including those with chronic medical conditions

[Varicella]
• Severity and incidence of complication / hospitalisation for Varicella disease.

Although GSK are more likely to support studies aligned to our current areas of interest for supported studies, we are interested in supporting studies that are innovative and contribute to scientific knowledge relating to a product, a medical condition or advancing a technology.



© 2001-2024 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.